$MGX

Metagenomi reported strong Q1 2026 financial results, with cash reserves of $140.2 million expected to fund operations through Q4 2027. The company advanced its MGX-001 hemophilia A program towards a late-2026 regulatory filing and 2027 trial initiation, while also showcasing in vivo proof-of-concept for its gene integration system and a compact CRISPR nuclease. Despite a decline in collaboration revenue, the company reduced R&D and G&A expenses, reinforcing its commitment to internally driven, potentially curative genetic treatments.